A share price of Atara Biotherapeutics Inc [ATRA] is currently trading at $18.09, up 1.17%. An important factor to consider is whether the stock is rising or falling in short-term value. The ATRA shares have gain 3.37% over the last week, with a monthly amount glided 33.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Atara Biotherapeutics Inc [NASDAQ: ATRA] stock has seen the most recent analyst activity on November 09, 2023, when Mizuho downgraded its rating to a Neutral and also revised its price target to $1 from $31. Previously, H.C. Wainwright downgraded its rating to Neutral on November 09, 2023. On November 09, 2023, downgrade downgraded it’s rating to In-line. Citigroup downgraded its rating to a Sell and decreased its price target to $3 on July 20, 2022. Stifel downgraded its rating to a Hold and reduced its price target to $5 on July 13, 2022. JP Morgan downgraded its rating to Neutral for this stock on July 13, 2022, but kept the price target unchanged to $10. In a note dated May 10, 2022, Citigroup downgraded an Neutral rating on this stock and revised its target price from $15 to $8.
Atara Biotherapeutics Inc experienced fluctuations in its stock price throughout the past year between $5.01 and $18.95. Currently, Wall Street analysts expect the stock to reach $25 within the next 12 months. Atara Biotherapeutics Inc [NASDAQ: ATRA] shares were valued at $18.09 at the most recent close of the market. An investor can expect a potential return of 38.2% based on the average ATRA price forecast.
Analyzing the ATRA fundamentals
Trailing Twelve Months sales for Atara Biotherapeutics Inc [NASDAQ:ATRA] were 151.93M which represents -91.41% decline. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.78, Equity is -0.42 and Total Capital is 2.17. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.91 points at the first support level, and at 17.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.31, and for the 2nd resistance point, it is at 18.52.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Atara Biotherapeutics Inc [NASDAQ:ATRA] is 1.02. On the other hand, the Quick Ratio is 1.02, and the Cash Ratio is 0.32. Considering the valuation of this stock, the price to sales ratio is 0.86 and price to earnings (TTM) ratio is 8.25.
Transactions by insiders
Recent insider trading involved Nguyen AnhCo, President and CEO, that happened on Nov 17 ’25 when 2915.0 shares were sold. Chief Accounting Officer, Grant-Huerta Yanina completed a deal on Nov 17 ’25 to sell 1804.0 shares. Meanwhile, Director Nguyen AnhCo bought 3346.0 shares on Nov 17 ’25.
